Scientists say bull blood could help treat stroke effects

Business Wire writes that the biopharmaceutical company will soon publish the results of the clinical phase of the HEMERA-1 trial testing PP-007. This will happen at the Breaking Science session during ISC 2023 in Dallas, Texas, and at the upcoming PAIRS conference in Dubai.

in 24News Breaker. Technology emerged telegraph channel. Subscribe so you don’t miss the latest and exciting news from the world of science!

PP-007 (pegylated bovine carboxyhemoglobin) is a new experimental biopharmaceutical product that improves microvascular blood flow by promoting oxygen transfer to oxygen-deficient (hypoxic) cells and tissues. In several stroke models, PP-007 has been shown to improve overall circulation. It provides oxygen to the hypoxic areas of the brain after occlusion of the great vessels (VC), reduces neuronal death and other consequences of stroke. HEMERA-1 is the first clinical trial of PP-007 using ZKS as an example.

Miami Neurology Institute Medical Director of Interventional Neuroradiology and the study’s Chief Scientist, Dr. Italo Linfante said: “Evaluation of PP-007 in patients with large vessel occlusion undergoing mechanical thrombus removal showed acceptable safety and tolerability. Mechanism of action PP-007 includes amplification of blood flow and vasodilation of the general circulation, targeted oxygen to ischemic areas for 24 hours. “This unique molecule can improve neurological performance and outcomes in stroke patients.”

“This study represents an important milestone in the clinical development of PP-007, based on our robust preclinical and clinical data for the treatment of ischemia/hypoxia. Ph.D. Ronald Jubin, vice president of early development at Prolong, with ongoing COVID -19 It is a very difficult time,” he said.

The HEMERA-1 study itself was conducted at several US medical centers. In addition to the large number of published non-clinical studies on ischemia/hypoxia and anemia, more than 270 subjects were treated with single or multiple doses of PP-007 for spontaneous cerebral hemorrhage, severe life-threatening anemia, and other diseases in 12 clinical studies. or conditions with an important component of ischemia/hypoxia, such as beta thalassemia and sickle cell anemia.

Scientists hope to reverse the idea that it is impossible to prevent the serious consequences of ischemic strokes and other conditions where there is a lack of oxygen in the tissues. This development will reduce the likelihood of complications and the associated mortality.

Earlier, Focus wrote that people with a certain blood type are at risk of having a stroke. The scientists reviewed nearly 50 different studies on genetics and strokes. In total, more than 600 thousand people were admitted – only 17 thousand of them suffered a stroke, the rest were absolutely healthy.